Web Analytics

fundsforNGOs

Grants and Resources for Sustainability

You are here: Home / Innovation / CFAs: Benefitting Cancer Patients with Locally Advanced or Metastatic Disease

CFAs: Benefitting Cancer Patients with Locally Advanced or Metastatic Disease

Deadline: 16-Sep-25

The European Commission (EC) is accepting applications for its program to Innovative surgery as the cornerstone of affordable multi-modal therapeutic interventions benefitting cancer patients with locally advanced or metastatic disease.

Scope
  • Cancer surgery represents the main first line treatment for solid tumours. While cancer patients with locally advanced or metastatic disease across Europe are often excluded from clinical studies, they would benefit from access to tailored, affordable, innovative, surgery-centred interventions, which are adapted to an increasingly precision oncology healthcare landscape.
Funding Information
  • The check will normally be done for the coordinator if the requested grant amount is equal to or greater than EUR 500 000, except for:
    • public bodies (entities established as a public body under national law, including local, regional or national authorities) or international organisations; and
    • cases where the individual requested grant amount is not more than EUR 60 000 (low value grant).
Eligible Activities
  • The following activities are generally eligible for grants under Horizon Europe:
    • Research and innovation actions (RIA) — Activities that aim primarily to establish new knowledge or to explore the feasibility of a new or improved technology, product, process, service or solution. This may include basic and applied research, technology development and integration, testing, demonstration and validation of a small-scale prototype in a laboratory or simulated environment.
    • Innovation actions (IA) — Activities that aim directly to produce plans and arrangements or designs for new, altered or improved products, processes or services. These activities may include prototyping, testing, demonstrating, piloting, large-scale product validation and market replication.
    • Coordination and support actions (CSA) — Activities that contribute to the objectives of Horizon Europe. This excludes research and innovation (R&I) activities, except those carried out under the ‘Widening participation and spreading excellence’ component of the programme (part of ‘Widening participation and strengthening the European Research Area’). Also eligible are bottom-up coordination actions which promote cooperation between legal entities from Member States and Associated Countries to strengthen the European Research Area, and which receive no EU co-funding for research activities.
    • Programme co-fund actions (CoFund) — A programme of activities established or implemented by legal entities managing or funding R&I programmes, other than EU funding bodies. Such a programme of activities may support: networking and coordination; research; innovation; pilot actions; innovation and market deployment; training and mobility; awareness raising and communication; and dissemination and exploitation. It may also provide any relevant financial support, such as grants, prizes and procurement, as well as Horizon Europe blended finance 30 or a combination thereof.
Expected Outcomes
  • Proposals under this topic should aim to deliver results that are directed and tailored towards, and to contribute to all of the following expected outcomes:
    • Patients have access to tailored, affordable, effective and–when appropriate–minimally-invasive surgery-centred, multi-modal treatment interventions targeting locally advanced or metastatic disease;
    • Researchers, innovators, SMEs and other professionals from different disciplines and sectors have access to innovative surgery-centred treatment technology and medical devices for further improvements and validation;
    • National healthcare providers, policymakers and authorities in European regions, Member States and Associated Countries have the evidence to implement affordable surgery-centred treatment solutions that benefit cancer patients with locally advanced or metastatic disease in their healthcare systems.
Eligibility Criteria
  • Any legal entity, regardless of its place of establishment, including legal entities from no associated third countries or international organisations (including international European research organisations) is eligible to participate.
  • A ‘legal entity’ means any natural or legal person created and recognised as such under national law, EU law or international law, which has legal personality and which may, acting in its own name, exercise rights and be subject to obligations, or an entity without legal personality.
  • Specific cases:
    • Affiliated entities — Affiliated entities (i.e. entities with a legal or capital link to a beneficiary which participate in the action with similar rights and obligations to the beneficiaries, but which do not sign the grant agreement and therefore do not become beneficiaries themselves) are allowed, if they are eligible for participation and funding.
    • Associated partners — Associated partners (i.e. entities which participate in the action without signing the grant agreement, and without the right to charge costs or claim contributions) are allowed, subject to any specific call/topic conditions.
    • Entities without legal personality — Entities which do not have legal personality under their national law may exceptionally participate, provided that their representatives have the capacity to undertake legal obligations on their behalf, and offer guarantees to protect the EU’s financial interests equivalent to those offered by legal persons.
    • EU bodies — Legal entities created under EU law including decentralised agencies may be part of the consortium, unless provided for otherwise in their basic act.
  • To be eligible for funding, applicants must be established in one of the following countries:
    • the Member States of the European Union, including their outermost regions:
      • Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden.
    • the Overseas Countries and Territories (OCTs) linked to the Member States:
      • Aruba (NL), Bonaire (NL), Curação (NL), French Polynesia (FR), French Southern and Antarctic Territories (FR), Greenland (DK), New Caledonia (FR), Saba (NL), Saint Barthélemy (FR), Sint Eustatius (NL), Sint Maarten (NL), St. Pierre and Miquelon (FR), Wallis and Futuna Islands (FR).
    • countries associated to Horizon Europe
      • Albania, Armenia, Bosnia and Herzegovina, Canada, Faroe Islands, Georgia, Iceland, Israel, Kosovo, Moldova, Montenegro, New Zealand, North Macedonia, Norway, Serbia, Tunisia, Türkiye, Ukraine, United Kingdom.

For more information, visit EC.